Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
Monteiro, I Califano, Raffaele Mountzios, G de Mello, R
Monteiro, I
Califano, Raffaele
Mountzios, G
de Mello, R
Citations
Altmetric:
Abstract
Despite recent advances, prognosis of patients with advanced lung cancer remains dismal. Owing to a better understanding of the interactions between immune system and tumor cells, immunotherapy has emerged as a promising therapeutic strategy. After the recent approval of nivolumab and the promising results with other immune checkpoint inhibitors, combination strategies are now subject of intensive research. Notwithstanding these successes, immunotherapy still holds significant drawbacks. As the target shifts from tumor cells to the tumor microenvironment, treatment paradigms are changing and several improvements are needed for optimal use in clinical practice. Robust biomarkers for patient selection and a reliable way of evaluating treatment response are high priorities. Herein we review current data on immune checkpoint inhibitors for lung cancer treatment.
Description
Date
2016-02
Publisher
Collections
Keywords
Type
Article
Citation
Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. 2016, 12 (4):551-64 Future Oncol